Abstract Background The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific). Methods Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype pro...
Abstract Background One of today’s greatest hurdles for cancer immunotherapy is the absence of infor...
Introduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ...
Individual cancers, even of the same cell type, express unique arrays of distinctive tumor antigens,...
Personalized vaccines against patient-unique tumor-associated antigens represent a promising new app...
Background: Despite recent advances in cancer immunotherapy and the development of various assays fo...
The profiling and monitoring of immune responses are key elements in the evaluation of the efficacy ...
The enzyme-linked immunosorbent spot (ELISpot) assay is one of the most commonly used methods to mea...
The ELISPOT assay is increasingly being used for the monitoring of the induction of antigen-reactive...
Quantification of antigen-specific CD8(+) T cells is important for monitoring infection, vaccination...
Cancer immunotherapies have shown substantial clinical activity for a subset of patients with epithe...
The enzyme-linked immunospot (ELISPOT) assay has advanced into a useful and widely applicable tool f...
Little is known about anti-tumor T cell activity in low antigenic but frequent tumor such as breast ...
The cloning of cancer Ags recognized by T cells has provided potentially new tools to enhance immuni...
Simple T cell assays specific for any chosen HLA class I or class II/peptide combination, are of eno...
Comprehensive immune monitoring requires that frequencies of T cells, producing different cytokines,...
Abstract Background One of today’s greatest hurdles for cancer immunotherapy is the absence of infor...
Introduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ...
Individual cancers, even of the same cell type, express unique arrays of distinctive tumor antigens,...
Personalized vaccines against patient-unique tumor-associated antigens represent a promising new app...
Background: Despite recent advances in cancer immunotherapy and the development of various assays fo...
The profiling and monitoring of immune responses are key elements in the evaluation of the efficacy ...
The enzyme-linked immunosorbent spot (ELISpot) assay is one of the most commonly used methods to mea...
The ELISPOT assay is increasingly being used for the monitoring of the induction of antigen-reactive...
Quantification of antigen-specific CD8(+) T cells is important for monitoring infection, vaccination...
Cancer immunotherapies have shown substantial clinical activity for a subset of patients with epithe...
The enzyme-linked immunospot (ELISPOT) assay has advanced into a useful and widely applicable tool f...
Little is known about anti-tumor T cell activity in low antigenic but frequent tumor such as breast ...
The cloning of cancer Ags recognized by T cells has provided potentially new tools to enhance immuni...
Simple T cell assays specific for any chosen HLA class I or class II/peptide combination, are of eno...
Comprehensive immune monitoring requires that frequencies of T cells, producing different cytokines,...
Abstract Background One of today’s greatest hurdles for cancer immunotherapy is the absence of infor...
Introduction: The Cytomegalovirus (CMV) is the major cause of morbidity and mortality in solid organ...
Individual cancers, even of the same cell type, express unique arrays of distinctive tumor antigens,...